Q1 2024 Earnings Forecast for LENZ Therapeutics, Inc. (NASDAQ:LENZ) Issued By Leerink Partnrs

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research report issued on Monday, April 15th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.51) for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

LENZ has been the topic of several other research reports. Piper Sandler started coverage on LENZ Therapeutics in a research report on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price target on the stock. SVB Leerink started coverage on LENZ Therapeutics in a research report on Monday. They set an “outperform” rating and a $32.00 price target on the stock. Citigroup started coverage on LENZ Therapeutics in a research report on Wednesday, April 10th. They set a “buy” rating and a $34.00 price target on the stock. Finally, William Blair started coverage on LENZ Therapeutics in a research report on Monday. They set an “outperform” rating on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, LENZ Therapeutics has a consensus rating of “Buy” and a consensus price target of $31.33.

LENZ Therapeutics Trading Down 11.1 %

Shares of LENZ Therapeutics stock opened at $17.70 on Wednesday. The company has a market capitalization of $147.26 million, a P/E ratio of -1.13 and a beta of 0.20. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82.

Insider Buying and Selling

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. bought 998,009 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were acquired at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the acquisition, the director now owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 38.40% of the stock is owned by insiders.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.